A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

Inclusion Criteria:

* Subject is able and willing to provide informed consent and sign an informed consent form.
* Subject must sign an authorization for the release of their protected health information.
* Subject must be ≥50 and ≤85 years of age at the time of enrollment.
* Subject must have hyperglycemia and/or diabetes as one of the following within 90 days prior to enrollment:

* All glycemic parameters must be measured in an outpatient setting

A. (1) Hemoglobin A1c (HbA1c) ≥ 6.5% present, OR

B. Any (2) PDMs present on consecutive or simultaneous testing:

* Fasting Blood Glucose (FBG) ≥126 mg/dl
* Hemoglobin A1c (HbA1c) ≥ 6.5%
* Random Blood Glucose (RBG) ≥200 mg/dl
* 2h Post Glucose (PG) ≥200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test), OR

C. Any (1) PDM present followed by an anti-diabetes medication

* Subject must have \>1 glycemic parameter measured in the 18 months prior to the elevated index lab without meeting inclusion criteria A, B, or C.
* Subject must be willing to provide blood samples (fasting) at baseline, 6, 12, and 24 months post-enrollment.
* Subject or authorized representative must be willing to complete a detailed questionnaire.

Exclusion Criteria:

* Subject must not have any past history of hyperglycemia and/or diabetes as defined by inclusion criteria A, B, or C

* Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion.
* Subject must not be on active treatment for cancer, carry a current diagnosis of any cancer, and/or investigated for suspicion of recurrence of past cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix).

* Ongoing work up for suspicion of pancreatic cancer is not an exclusion.
* Subject must not have any past history of pancreatic cancer.
* Subject must not be on anti-diabetes medications prior to the elevated index lab.
* Subject must not be on chronic or acute use of steroid medications within 90 days of the elevated index lab.

* Allowed: Nasal, topical steroids, oral budesonide, ophthalmic
* Subject must not have had a recent (within 1 week of the elevated index lab) intra-articular steroid injection.
* In the physician's and/or investigator's judgement, subject does not have any co-morbidities that limit the subject's participation in the study.